Spyre Plunges, While This Setback Isn't Shaking Analysts

Spyre Therapeutics took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing. The post Spyre Plunges, While This Setback Isn't Shaking Analysts appeared first on Investor's Business Daily.